-
公开(公告)号：KR1020140086210A
公开(公告)日：2014-07-08
申请号：KR1020120156408
申请日：2012-12-28
Applicant: 한국식품연구원
IPC: A61K31/47 , A61K31/435 , A61P3/04 , A61P29/00
CPC classification number: A61K31/4741 , A23L33/10 , A61K31/4748 , Y10S514/866 , Y10S514/886 , Y10S514/909
Abstract: The present invention relates to a composition for treating obesity-induced inflammation, wherein the composition contains tetrandrine as an active ingredient. The composition of the present invention induces the expression of adiponectin and decreases the expression of IL-6 and MCP-1 which are involved in obesity-mediated inflammation reaction so that obesity-induced inflammation can be prevented and treated.
Abstract translation: 本发明涉及一种用于治疗肥胖症引起的炎症的组合物，其中该组合物含有四片丹宁作为活性成分。 本发明的组合物诱导脂联素的表达并降低参与肥胖介导的炎症反应的IL-6和MCP-1的表达，从而可以预防和治疗肥胖诱发的炎症。
-
公开(公告)号：KR101327938B1
公开(公告)日：2013-11-14
申请号：KR1020110037694
申请日：2011-04-22
Applicant: 한국식품연구원
IPC: A61K31/215 , A61K31/21 , A61K9/48 , A61P3/04
Abstract: 본 발명은 메틸 카페이트를 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 약학적 조성물과 건강기능식품에 관한 것이다. 상기 조성물 또는 건강기능식품은 지방세포분화 저해 효능이 우수하다.
-
公开(公告)号：KR101241435B1
公开(公告)日：2013-03-11
申请号：KR1020100077227
申请日：2010-08-11
Applicant: 호서대학교 산학협력단 , 한국식품연구원
Abstract: 메주 추출물을 유효성분으로 함유하는 항당뇨제 및 당뇨 개선용 건강기능식품이 제공된다. 본 발명의 항당뇨제 및 건강기능식품은 생체 내에서 혈당을 떨어뜨려줄 뿐만 아니라, 인슐린 저항성을 감소시킴으로써 당뇨병 특히 인슐린 저항성을 갖는 제2형 당뇨병의 치료 및 개선에 유효하며, 아주 오래전부터 아무런 부작용 없이 사용되어온 메주로부터 제조되므로, 안전성 면에서 매우 효과적이다.
-
34.发明授权
公开(公告)号：KR101209889B1
公开(公告)日：2012-12-10
申请号：KR1020100045593
申请日：2010-05-14
IPC: A61K36/232 , A61K31/37 , A61P3/04 , A61P3/00
Abstract: 본발명은당귀의주성분인데쿠르신으로부터합성된유도체인데쿠시놀벤조에이트(Decursinol benzoate)를이용한비만예방용또는비만치료용조성물에관한것으로써, 보다상세하게는상기데쿠시놀벤조네이트는 AMPK(5' adenosine monophosphate-activated protein kinase)활성능을가짐으로써지방산합성을억제하는것을특징으로갖거나, PPAR-GAMMA(Peroxisome proliferator-activated receptor gamma)의발현및 전사활성을억제하는것을특징으로가질수 있다.
-
35.发明授权발효 청국장 분말 또는 발효 청국장 추출 분획물을 유효성분으로 함유하는 허혈성 뇌질환의 예방 및 치료용 조성물 有权包含发酵中心的粉末或用于治疗和预防缺血性损害疾病的发酵中枢囊的提取部分的组合物
公开(公告)号：KR101154220B1
公开(公告)日：2012-06-21
申请号：KR1020080116566
申请日：2008-11-24
Applicant: 한국식품연구원
Abstract: 본 발명은 발효 청국장 분말 또는 발효 청국장 추출 분획물을 유효성분으로 함유하는 허혈성 뇌질환의 예방 및 치료용 조성물에 관한 것으로서, 상세하게는 본 발명의 발효 청국장 분말 또는 발효 청국장 추출 분획물은 부신유래의 PC12세포주를 이용한 저산소환경에 의한 세포사 억제 실험 및 저빌을 이용한 허혈성 뇌질환 실험을 통해 PC12세포주 또는 해마조직 CA1 영역의 신경세포 손상을 효과적으로 예방하는 것을 확인함으로서, 허혈성 뇌질환의 예방 및 치료용 약학조성물 및 건강기능식품으로 유용하게 이용될 수 있다.
발효 청국장, 허혈성 뇌질환, 신경세포-
Patent Agency Ranking36.发明公开
公开(公告)号：KR1020120061018A
公开(公告)日：2012-06-12
申请号：KR1020100109058
申请日：2010-11-04
Applicant: 한국식품연구원
Abstract: PURPOSE: A pharmaceutical composition and health functional food containing p-xyleneselenocyanate are provided to prevent and treat obesity and lipid-related metabolic disorders. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic disorders contains 0.1-50 wt% of p-xylene selenocyanate as an active ingreedient. The metabolic diseases include diabetes, hyperlipidemia, fatty liver, artheriosclerosis, hypertension, cardiovascular diseases, or a combination thereof. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, oral formulation of aerosol, external use formulation, suppository, or sterilized injection solution. A health functional food for preventing and relieving obesity and lipid-related metabolic disorders contains p-xylene selenocyanate as an active ingredient.
Abstract translation: 目的：提供含有对二甲苯硒异氰酸酯的药物组合物和保健功能食品，用于预防和治疗肥胖症和与脂质有关的代谢紊乱。 构成：用于预防和治疗肥胖症和与脂质有关的代谢紊乱的药物组合物含有0.1-50重量％的对二甲苯硒氰酸酯作为活性成分。 代谢疾病包括糖尿病，高脂血症，脂肪肝，神经硬化，高血压，心血管疾病或其组合。 组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气雾剂口服制剂，外用制剂，栓剂或灭菌注射液的形式制造。 用于预防和减轻肥胖症和与脂质有关的代谢紊乱的健康功能食品含有对二甲苯硒氰酸酯作为活性成分。
-
公开(公告)号：KR1020120061016A
公开(公告)日：2012-06-12
申请号：KR1020100109049
申请日：2010-11-04
Applicant: 한국식품연구원
Abstract: PURPOSE: A pharmaceutical composition containing sulforaphane is provided to suppress adipocyte differentiation and to prevent and treat obesity and metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid metabolic diseased contains 0.1-50 wt% of sulforaphane as an active ingredient. The sulforaphane includes R,S-sulforaphane, R-sulforaphane, or S-sulforaphane. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, aerosol, suppository, or sterilization injection solution. A health functional food for preventing and relieving obesity and lipid metabolic diseases contains sulforaphane as an active ingredient.
Abstract translation: 目的：提供含有萝卜硫素的药物组合物，以抑制脂肪细胞分化，预防和治疗肥胖症和代谢疾病。 构成：用于预防和治疗肥胖症和脂质代谢疾病的药物组合物含有0.1-50重量％的萝卜硫素作为活性成分。 萝卜硫烷包括R，S-四氢萘烷，R-萝卜硫烷或S-萝卜硫烷。 该组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气雾剂，栓剂或灭菌注射溶液的形式制备。 用于预防和减轻肥胖和脂质代谢疾病的健康功能食品含有萝卜硫素作为活性成分。
-
公开(公告)号：KR1020120003779A
公开(公告)日：2012-01-11
申请号：KR1020100064564
申请日：2010-07-05
Applicant: 한국식품연구원
IPC: A61K36/185 , A61P3/04 , A61P3/00
Abstract: PURPOSE: A composition containing Pittosporum heterophyllum extract for preventing or treating obesity is provided to suppress differentiation of adipocytes and to activate AMPK(5'AMP-activated protein kinase). CONSTITUTION: A composition for preventing and treating obesity contains 0.1-99.9 wt% of Pittosporum heterophyllum extract as an active ingredient. The composition is a pharmaceutical composition or food additive composition. A food composition for preventing and treating obesity contains Pittosporum heterophyllum extract as an active ingredient. The composition is manufactured in the form of a pill, powder, granule, tablet, capsule, or beverage.
Abstract translation: 目的：提供含有用于预防或治疗肥胖症的Pittosporum heterophyllum提取物的组合物，以抑制脂肪细胞的分化并激活AMPK（5'AMP激活的蛋白激酶）。 构成：用于预防和治疗肥胖症的组合物含有0.1-99.9重量％的作为活性成分的Pittosporum heterophyllum提取物。 该组合物是药物组合物或食品添加剂组合物。 用于预防和治疗肥胖症的食物组合物含有作为活性成分的孔雀虱提取物。 组合物以丸剂，粉剂，颗粒剂，片剂，胶囊剂或饮料的形式制备。
-
公开(公告)号：KR1020110137124A
公开(公告)日：2011-12-22
申请号：KR1020100057167
申请日：2010-06-16
Applicant: 한국식품연구원
CPC classification number: H04N21/4622 , G06K19/0723 , H04H20/93 , H04H60/63 , H04H60/90 , H04N21/4722
Abstract: PURPOSE: A system and a method for providing information are provided to supply food information related to the broadcasting information with the broadcasting information which is provided from a corresponding set top box to a mobile communication terminal. CONSTITUTION: A broadcasting company interface unit(34) provides set top box identifying information to an external broadcasting company if set top box identification information exists in the tag information. The broadcasting company interface unit receives the channel information of the broadcasting which is provided from a corresponding set top box from an external broadcasting company. An information extracting unit(35) respectively extracts the food information and the broadcasting information from a database by using the channel information received through the broadcasting interface unit. An information providing unit(36) provides the extracted food information and the broadcasting information to a mobile communication terminal.
Abstract translation: 目的：提供一种用于提供信息的系统和方法，以将与广播信息相关的食品信息与从相应的机顶盒提供给移动通信终端的广播信息相提供。 规定：如果标签信息中存在机顶盒识别信息，则广播公司接口单元（34）向外部广播公司提供机顶盒识别信息。 广播公司接口单元从外部广播公司接收从相应的机顶盒提供的广播的频道信息。 信息提取单元（35）通过使用通过广播接口单元接收的频道信息从数据库中分别提取食物信息和广播信息。 信息提供单元（36）将所提取的食物信息和广播信息提供给移动通信终端。
-
公开(公告)号：KR1020100044623A
公开(公告)日：2010-04-30
申请号：KR1020080103831
申请日：2008-10-22
CPC classification number: C40B40/08 , C07K14/47 , C12Q1/6844 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/53
Abstract: PURPOSE: A specific gene MML1 specifically developing at a liver tissue of a mouse is provided to reduce a false positive from a diagnosis research of liver related disease and to enable an easier diagnosis of the liver related disease. CONSTITUTION: A specific gene MML1 specifically developing at a liver tissue is formed with an amino acid sequence. A micro array to diagnosis liver related disease comprises the MML1 gene. The micro array also comprises an antibody for the MML1 gene. A kit to diagnose the liver related disease comprises a primer set and a reagent for RT-PCR(reverse transcriptase polymerase chain reaction). The diagnosing method for the liver related disease of a mammal comprises a step of separating the total RNA from a mammal sample, a step of amplifying a target sequence by performing the RT-PCR using the primer set, and a step of detecting the result. The mammal is non human.
Abstract translation: 目的：提供特异性基因MML1特异性在小鼠肝组织发育，以减少肝脏相关疾病诊断研究中的假阳性，并能够更容易地诊断肝脏相关疾病。 构成：用氨基酸序列形成特异性在肝组织发育的MML1基因。 用于诊断肝脏相关疾病的微阵列包括MML1基因。 微阵列还包含用于MML1基因的抗体。 用于诊断肝脏相关疾病的试剂盒包括引物组和用于RT-PCR（逆转录酶聚合酶链式反应）的试剂。 哺乳动物的肝脏相关疾病的诊断方法包括从哺乳动物样品中分离总RNA的步骤，通过使用引物组进行RT-PCR扩增靶序列的步骤和检测结果的步骤。 哺乳动物是非人类的。
-
-
-
-
-
-
-
-
-
Search Results
109
records
(took 0.03 seconds)
